Alpha Tau Medical
Logotype for Alpha Tau Medical Ltd

Alpha Tau Medical (DRTS) investor relations material

Alpha Tau Medical Study update summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Alpha Tau Medical Ltd
Study update summary16 Nov, 2026

Trial design and treatment

  • REGAIN is a prospective, open-label, single-arm study expanded from 10 to 20 patients; eight treated, with six reaching response assessment and planned 12-month follow-up.

  • Eligible patients have IDH wild-type grade 4 glioma, up to three recurrences and tumors under 3 cm; treatment uses image-guided stereotactic implantation of radium-224-loaded titanium sources.

  • Alpha DaRT uses radium-224 decay to release daughter atoms into tumors; alpha radiation acts independently of oxygen and causes double-strand DNA breaks, while particles travel 40–90 microns in tissue.

Interim efficacy and feasibility

  • Planned sources were deployed with tumor coverage in all treated patients; no unanticipated serious adverse events were reported.

  • All eight patients were alive at median follow-up of ~7 months; among six assessed, best response was five complete and one partial response, for a 100% overall response rate.

  • No recurrence was observed at treated sites; one progression occurred at a distant location. Response confirmation remains ongoing as additional scans are collected.

  • One grade 3 serious adverse event, a seizure with Todd's paralysis, resolved after rehabilitation and steroids; the patient returned to baseline.

  • Suspected necrosis or treatment changes were under evaluation in two patients and were asymptomatic; clinicians noted that later scans are needed to distinguish treatment effects from progression.

Follow-up and development plans

  • Enrollment is expanding across multiple sites, including NYU and Barrow; an additional interim GBM data update is expected when the first five patients complete six months, targeted for Q1 2027.

  • The study uses MRI and RANO for response assessment; amino acid PET is used at Ohio State to help evaluate ambiguous lesions, but is not standard across the trial.

  • FDA discussions continue on data maturity and a potential regulatory pathway; the study has Breakthrough Device Designation and is part of the Total Product Life Cycle Advisory Program.

  • Management expects Hudson, New Hampshire manufacturing capacity for commercial quantities by FDA approval; a focused launch strategy would target high-volume U.S. centers.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Alpha Tau Medical earnings date

Logotype for Alpha Tau Medical Ltd
Q3 202623 Nov, 2026
Alpha Tau Medical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Alpha Tau Medical earnings date

Logotype for Alpha Tau Medical Ltd
Q3 202623 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company. The company specializes in the research, development, and commercialization of its proprietary Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) technology. This innovative therapy is designed for the treatment of solid tumors, with the ability to deliver highly potent and localized alpha radiation, minimizing damage to surrounding healthy tissues. Alpha Tau is focused on addressing unmet needs in various cancer types, including skin, oral, pancreatic, and prostate cancers, among others. The company is headquartered in Jerusalem, Israel, and its shares are listed on the NASDAQ.